Detalles de la búsqueda
1.
Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns.
BMC Infect Dis
; 20(1): 161, 2020 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085740
2.
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.
Haematologica
; 102(5): 895-902, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183846
3.
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Cancer
; 122(13): 2050-6, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27191689
4.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Blood
; 124(16): 2498-506, 2014 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25202139
5.
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Ann Hematol
; 95(12): 2033-2041, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27738789
6.
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Oncologist
; 18(1): 27-36, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23299777
7.
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Blood
; 118(4): 865-73, 2011 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-21562045
8.
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood
; 116(19): 3743-50, 2010 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20628153
9.
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Haematologica
; 97(12): 1925-8, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22689676
10.
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Eur J Haematol
; 89(1): 16-27, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22469559
11.
Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients.
PLoS One
; 17(8): e0273186, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35980979
12.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Br J Haematol
; 153(2): 212-21, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21375521
13.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med
; 359(9): 906-17, 2008 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-18753647
14.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Blood
; 114(8): 1489-97, 2009 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19498019
15.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Eur J Haematol
; 86(1): 23-31, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20874823
16.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Eur J Haematol
; 86(5): 372-84, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21366694
17.
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
Cancer Res
; 78(5): 1155-1168, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29259009
18.
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.
Haematologica
; 92(10): 1399-406, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18024376
19.
Spontaneous chronic subdural hematomas in human immunodeficiency virus-infected patients with normal platelet count and no appreciable brain atrophy: Two case reports and review of literature.
Surg Neurol Int
; 7(Suppl 15): S437-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27308093
20.
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
J Clin Oncol
; 31(26): 3279-87, 2013 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23897961